Since cognitive impairments are core FXS phenotypes, it is postulated that most therapeutic interventions targeting key mechanisms related to FMRP deficit (e.g., mGluR5 antagonists, trofinetide) would have an impact on global or specific cognitive domains, including communication abilities [20, 21]. Here, GRM5 is linked to fragile X syndrome.